Gastrointestinal-sparing anti-inflammatory drugs: The development of nitric oxide-releasing NSAIDs

Drug Development Research

Volumn 42, Issue 3-4, 1997, Pages 144-149

  Wallace, John L ^a   Elliott, Susan N ^a   Del Soldato, Piero ^b   McKnight, Webb ^a   Sannicolo, Franco ^c   Cirino, Giuseppe ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b NicOx SA   (France)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Analgesic; Anti inflammatory; Anti thrombotic; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG SAFETY; GASTROINTESTINAL TOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PROSTAGLANDIN SYNTHESIS; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOSIS PREVENTION;

EID: 0031391435     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199711/12)42:3/4<144::AID-DDR5>3.0.CO;2-Q     Document Type: Review

References (36)

1. Brown JF, Hanson PJ, Whittle BJR (1992): Nitric oxide donors increase mucus gel thickness in rat stomach. Eur J Pharmacol 223:101-104.
2. Cryer B, Luk G, Feldman M (1995): Effects of very low doses of aspirin (ASA) on gastric, duodenal and rectal prostaglandins (PGs) and mucosal injury (Abstract). Gastroenterology 108:A77.
3. Cuzzolin L, Conforti A, Adami A, Lussignoli S, Memestrina F, Del Soldato P, Benoni G (1995): Anti-inflammatory potency and gastrointestinal toxicity of a new compound, NO-naproxen. Pharmacol Res 31:61-65.
4. Davies NM, Roseth AG, Appleyard CB, McKnight W, Del Soldato P, Calignano A, Cirino G, Wallace JL (1996): NO-naproxen vs. naproxen: Ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 11:69-79.
5. Douthwaite AH, Lintott SAM (1938): Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 2:1222-1225.
6. Elliott SN, McKnight W, Cirino G, Wallace JL (1995): A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in the rat. Gastroenterology 109:524-530.
7. Fujihara CK, Malheiros DMAC, Antunes E, Donato JL, Santos MM, Sena CR, De Nucci G, Zatz R (1995): Nitroflurbiprofen, a novel nonsteroidal anti-inflammatory drug, limits glomerular injury in the remnant model (Abstract). J Am Soc Nephrol 6:1012.
8. Garner A (1992): Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and diseases. Scand J Gastroenterol 27(193):83-89.
9. Graham DY (1990): The relationship between nonsteroidal anti-inflammatory drug use and peptic ulcer disease. Gastroenterol Clin North Am 19:171-182.
10. JECFA (1996): Toxicological evaluation of certain food additives and contaminants. 44th Meeting of the Joint FAO/WHO Expert Committee on Food Additives, International Programme on Chemical Safety, World Health Organization.
11. Kubes P, Suzuki M, Granger DN (1991): Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88:4651-4655.
12. Lopez-Belmonte J, Whittle BJR, Moncada S (1993): The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa. Br J Pharmacol 108:73-78.
13. MacNaughton WK, Cirino G, Wallace JL (1989): Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 45:1869-1876.
14. Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC (1992): Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost 68:1-6.
15. Mitchell JA, Cirino G, Akarasereenont P, Wallace JL, Flower RJ, Vane JR (1994): Flurbinitroxybutylester: A novel anti-inflammatory drug devoid of ulcerogenic activity, inhibits cyclo-oxygenase-1 and cyclooxgenase-2. Can J Physiol Pharmacol 72:270.
16. Moncada S, Palmer RMJ, Higgs EA (1991): Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142.
17. Patrono C (1994): Aspirin as an antiplatelet drug. N Engl J Med 330:1287-1294.
18. Reuter BK, Cirino G, Wallace JL (1994): Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci 55: PL1-PL8.
19. Reuter BK, Davies NM, Wallace JL (1997): Nonsteroidal anti-inflammatory drug-enteropathy in rats: Role of permeability, bacteria and enterohepatic circulation. Gastroenterology 112:109-117.
20. The SALT Collaborative Group (1991): Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338:1345-1349.
21. Segasothy M, Samad SA, Zulfigar A, Bennett WM (1994): Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 24:17-24.
22. Soll AH, Weinstein WM, Kurata J, McCarthy D (1991): Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 114:307-319.
23. Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235.
24. Wallace JL (1993): Gastric ulceration: Critical events at the neutrophil-endothelium interface. Can J Physiol Pharmacol 71:98-102.
25. Wallace JL, Tigley AW (1995): New insights into prostaglandins and mucosal defence. Aliment Pharmacol Ther 9:227-235.
26. Wallace JL, Keenan CM, Granger DN (1990): Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 259:G462-G467.
27. Wallace JL, Arfors K-E, McKnight GW (1991): A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 100:878-883.
28. Wallace JL, McKnight W, Miyasaka M, Tamatani T, Paulson J, Anderson DC, Granger DN, Kubes P (1993): Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol 265:G993-G998.
29. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G (1994a): Novel nonsteriodal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107:173-179.
30. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G (1994b): Adiclofenac derivative without ulcerogenic properties. Eur J Pharmacol 237:249-255.
31. Wallace JL, Reuter BK, Cirino G (1994c): Nitric oxide releasing NSAIDs: A novel approach for reducing gastropathy. J Gastroenterol Hepatol 9:S40-S44.
32. Wallace JL, McKnight W, Del Soldato P, Cirino G (1995a): Anti-thrombotic properties of a nitric oxide-releasing, gastric sparing aspirin derivative. J Clin Invest 96:2711-2718.
33. Wallace JL, Pittman QJ, Cirino G (1995b): Nitric oxide-releasing NSAIDs: A novel class of GI-sparing anti-inflammatory drugs. Agents Actions 46:S121-S129.
34. Wallace JL, McKnight W, Wilson TL, Del Soldato P, Cirino G (1997a): Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: Role of neutrophils. Am J Physiol 273:G1246-1251.
35. Wallace JL, McKnight W, Wilson TL, Cirino G, Del Soldato P, Davies NM (1997b): Nitric oxide releasing aspirin derivative (NCX 4016): A gastric-sparing anti-thrombotic drug (Abstract). Gastroenterology 112:A325.
36. Whittle BJR (1993): Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: Integrity in the balance. Br J Pharmacol 110:3-17.